Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BONTRIL vs TEPANIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bontril (phendimetrazine) is a sympathomimetic amine that acts as an appetite suppressant. Its mechanism involves stimulating the hypothalamus to release norepinephrine and dopamine, which reduces hunger cues. It is a prodrug that is metabolized to the active agent phenmetrazine, which inhibits reuptake and increases release of norepinephrine and dopamine in the central nervous system.
TEPANIL (diethylpropion) is a sympathomimetic amine that acts as a norepinephrine reuptake inhibitor in the hypothalamus, increasing norepinephrine levels in the synaptic cleft, which stimulates beta-2 adrenergic receptors, leading to appetite suppression.
FDA-approved for management of obesity as a short-term adjunct (few weeks) in a regimen of weight reduction based on caloric restriction, exercise, and behavior modification. Off-label uses are not well documented due to limited evidence.
FDA-approved: Short-term (8-12 weeks) adjunctive therapy for weight management in patients with a body mass index (BMI) ≥30 kg/m² or BMI ≥27 kg/m² in the presence of obesity-related risk factors (e.g., hypertension, diabetes, dyslipidemia). Off-label: None commonly recognized.
BONTRIL 50 mg orally once daily, with or without food.
25 mg orally three times daily, 1 hour before meals, or 75 mg extended-release orally once daily in the morning.
18-24 hours; prolonged in renal impairment (up to 40 hours) requiring dose adjustment.
4-6 hours; clinical context: requires multiple daily dosing for sustained anorectic effect
Phendimetrazine is extensively metabolized in the liver, primarily via N-demethylation to its active metabolite phenmetrazine. Minor pathways include hydroxylation and conjugation. Cytochrome P450 enzymes are involved, though specific isoforms are not fully characterized.
Hepatic metabolism via CYP450 isoenzymes, primarily N-dealkylation and deamination. Active metabolites include N-ethyl- and N,N-diethyl- derivatives.
Primarily renal (60-70% unchanged) with minor biliary/fecal (10-15% as metabolites).
Renal: 90% (as metabolites and unchanged drug), Fecal: <10%
85-90% bound to albumin and alpha-1-acid glycoprotein.
30-40% bound to albumin
3-5 L/kg; indicates extensive tissue distribution.
3-4 L/kg; indicates extensive tissue distribution
Oral: 70-80% (first-pass metabolism); IV: 100%.
Oral: 60-70% due to first-pass metabolism
GFR >60 m L/min: no adjustment. GFR 30-60 m L/min: reduce dose to 25 mg once daily. GFR <30 m L/min: use is not recommended.
Contraindicated in end-stage renal disease. For GFR <30 m L/min: not recommended. For GFR 30-59 m L/min: use with caution and monitor for adverse effects.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose to 25 mg once daily. Child-Pugh Class C: use is contraindicated.
Contraindicated in severe hepatic impairment. For Child-Pugh Class B: reduce dose by 50% or consider alternative. For Child-Pugh Class A: no adjustment required.
Weight-based: 1 mg/kg orally once daily, with a maximum of 50 mg. Not recommended for children weighing less than 10 kg.
Not recommended for use in children below 16 years of age due to lack of safety and efficacy data.
Start at 25 mg orally once daily; may increase to 50 mg after 2 weeks if tolerated and renal function is adequate (Cr Cl >60 m L/min).
Starting dose of 25 mg once daily in the morning, with slow titration upwards. Monitor for cardiovascular and psychiatric effects due to increased sensitivity.
None
None.
Risk of abuse, dependence, and tolerance; monitor for signs of addiction.,May cause serious cardiovascular events including pulmonary hypertension and valvular heart disease, especially with long-term use.,May impair ability to drive or operate machinery due to dizziness or blurred vision.,Use with caution in patients with hypertension, hyperthyroidism, glaucoma, or history of drug abuse.,Concomitant use with other sympathomimetics or MAO inhibitors can cause hypertensive crisis.,Not recommended for use in patients with a history of epilepsy or those taking other anorectic agents.
Pulmonary hypertension: Cases of primary pulmonary hypertension (PPH) have been reported; avoid in patients with known pulmonary hypertension.,Valvular heart disease: Association with regurgitant cardiac valvular disease; avoid in patients with structural cardiac abnormalities.,Serotonin syndrome: Risk when co-administered with serotonergic drugs or MAOIs; allow 14 days after MAOI discontinuation.,CNS stimulation: May cause dizziness, insomnia, and euphoria; avoid with alcohol or other CNS stimulants.,Tolerance/dependence: Tolerance develops with prolonged use; potential for psychological dependence; limit use to 8-12 weeks.,Hypertension: Monitor blood pressure; exacerbate pre-existing hypertension.
Known hypersensitivity to phendimetrazine or any component of the formulation.,History of cardiovascular disease including coronary artery disease, arrhythmias, or congestive heart failure.,Hypertension (moderate to severe).,Hyperthyroidism.,Glaucoma.,History of drug abuse or alcoholism.,Concurrent use of monoamine oxidase inhibitors or within 14 days of such use.,Pregnancy and breastfeeding.,Agitated states.,History of seizure disorders.
History of pulmonary hypertension or valvular heart disease.,Hyperthyroidism.,Glaucoma.,Agitated states.,History of drug abuse.,Concurrent use or within 14 days of MAOIs.,Hypersensitivity to diethylpropion or sympathomimetic amines.,Pregnancy and lactation.
Avoid high-fat meals as they may delay absorption of oral formulations. No specific food-drug interactions known; however, anticholinergic effects may be exacerbated by alcohol.
Avoid caffeine, as it may increase stimulant effects and risk of palpitations. Avoid alcohol, which can potentiate CNS effects and increase seizure risk. Take with food if gastrointestinal upset occurs.
BONTRIL is classified as FDA Pregnancy Category X. First trimester: high risk of major congenital malformations including neural tube defects, cardiovascular anomalies, and cleft palate. Second and third trimesters: risk of fetal growth restriction, oligohydramnios, and neonatal respiratory depression if used near term.
Pregnancy Category X. TEPANIL (diethylpropion) is contraindicated in pregnant women due to anorectic effects potentially causing fetal malnutrition and growth restriction. First trimester exposure may increase risk of neural tube defects, though human data limited. Second and third trimester exposure may lead to reduced birth weight and neonatal withdrawal symptoms including irritability and tremors.
No data available on excretion into human breast milk. M/P ratio unknown. Due to potential for serious adverse effects in nursing infants, breastfeeding is contraindicated during BONTRIL therapy.
Excreted into breast milk; milk-to-plasma ratio not established. Potential for adverse effects in nursing infants including irritability and feeding difficulties. Contraindicated in breastfeeding due to risk of infant exposure and lack of safety data.
No dose adjustment required for pregnancy. However, due to teratogenicity, BONTRIL should be discontinued before conception or as soon as pregnancy is diagnosed.
No dose adjustment is recommended or studied in pregnancy as drug is contraindicated. Pharmacokinetic changes in pregnancy (increased volume of distribution, enhanced hepatic metabolism) would likely reduce drug exposure; however, given fetal risks, use is not justified. Avoid use entirely.
BONTRIL (hyoscyamine) is an anticholinergic used for GI spasms; avoid in patients with glaucoma, myasthenia gravis, or obstructive uropathy. Onset of action is 2-3 minutes IV; monitor for heat stroke in high ambient temperatures due to decreased sweating.
TEPANIL is a schedule IV controlled substance; assess for history of substance abuse before prescribing. Avoid use in patients with cardiovascular disease, hyperthyroidism, glaucoma, or agitated states. Monitor blood pressure and heart rate regularly. Use only for short-term (8-12 weeks) as tolerance develops. Do not combine with MAOIs or within 14 days of MAOI use. May cause insomnia; advise last dose before 6 PM.
Do not drive or operate machinery until you know how this medication affects you, as it may cause dizziness or blurred vision.,Avoid alcohol and other CNS depressants as they may increase sedation.,Report immediately if you experience eye pain, difficulty urinating, or rapid heartbeat.,Use caution in hot weather; this drug reduces sweating and increases risk of heat stroke.
Take exactly as prescribed; do not increase dose or frequency due to abuse potential.,May cause dizziness or blurred vision; avoid driving until you know how this medicine affects you.,Report chest pain, shortness of breath, or leg swelling immediately.,Avoid alcohol and caffeine-containing products while taking this medication.,Do not stop abruptly; taper under medical supervision to avoid withdrawal symptoms.,Tell your doctor if you have a history of drug abuse or mental health issues.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BONTRIL vs TEPANIL, answered by our medical review team.
BONTRIL is a Sympathomimetic Anorectic that works by Bontril (phendimetrazine) is a sympathomimetic amine that acts as an appetite suppressant. Its mechanism involves stimulating the hypothalamus to release norepinephrine and dopamine, which reduces hunger cues. It is a prodrug that is metabolized to the active agent phenmetrazine, which inhibits reuptake and increases release of norepinephrine and dopamine in the central nervous system.. TEPANIL is a Sympathomimetic anorectic that works by TEPANIL (diethylpropion) is a sympathomimetic amine that acts as a norepinephrine reuptake inhibitor in the hypothalamus, increasing norepinephrine levels in the synaptic cleft, which stimulates beta-2 adrenergic receptors, leading to appetite suppression.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BONTRIL and TEPANIL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BONTRIL is: BONTRIL 50 mg orally once daily, with or without food.. The standard adult dose of TEPANIL is: 25 mg orally three times daily, 1 hour before meals, or 75 mg extended-release orally once daily in the morning.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BONTRIL and TEPANIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BONTRIL is classified as Category C. BONTRIL is classified as FDA Pregnancy Category X. First trimester: high risk of major congenital malformations including neural tube defects, cardiovascular anomalies, and cleft p. TEPANIL is classified as Category C. Pregnancy Category X. TEPANIL (diethylpropion) is contraindicated in pregnant women due to anorectic effects potentially causing fetal malnutrition and growth restriction. First tr. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.